Tacrolimus eye drops can be used to treat refractory vernal keratoconjunctivitis


Topical 0.0005% tacrolimus eye drops are a safe and effective treatment for refractory vernal keratoconjunctivitis (VKC).

Topical 0.0005% tacrolimus eye drops are a safe and effective treatment for refractory vernal keratoconjunctivitis (VKC), according to data published in Eye.

Dr A. Kheirkhah et al., Farabi Eye Hospital, Eye Research Center, Tehran University of Medical Sciences, Iran, conducted the prospective study on 20 eyes of 10 patients with refractory VKC. Patients stopped using other medications and were treated with 0.0005% tacrolimus eye drops four times daily. The outcome measures included changes in subjective symptoms, objectives symptoms post-treatment and the progression of potential complications.

Patients presented with symptoms including itching, redness, photosensitivity, foreign body sensation and mucus discharge. After treatment all symptoms demonstrated signs of improvement. Objective signs such as conjunctival hyperaemia, conjunctival papillary hypertrophy, giant papillae, limbal hypertrophy, corneal punctate epithelial erosions, and corneal pannus also showed improvement.

There were no ocular complications associated with tacrolimus and additional treatment for further relief was not necessary. The study suggests the long-term use of tacrolimus for the most effective results.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.